| Autor: |
Pérez-Montes de Oca A; Endocrine and Nutrition Service, Germans Trias i Pujol Hospital and Research Institute, Universitat Autònoma de Barcelona, 08916 Badalona, Spain., Julián MT; Endocrine and Nutrition Service, Germans Trias i Pujol Hospital and Research Institute, Universitat Autònoma de Barcelona, 08916 Badalona, Spain., Ramos A; Endocrine and Nutrition Service, Germans Trias i Pujol Hospital and Research Institute, Universitat Autònoma de Barcelona, 08916 Badalona, Spain., Puig-Domingo M; Endocrine and Nutrition Service, Germans Trias i Pujol Hospital and Research Institute, Universitat Autònoma de Barcelona, 08916 Badalona, Spain., Alonso N; Endocrine and Nutrition Service, Germans Trias i Pujol Hospital and Research Institute, Universitat Autònoma de Barcelona, 08916 Badalona, Spain. |
| Abstrakt: |
Gut microbiota can contribute to the development and progression of non-alcoholic fatty liver disease (NAFLD). In fact, some specific changes of gut microbiota are observed in patients in what is called dysbiota. There has been a lot of investigation by using a variety of interventions, including diet, showing the possibility to modify components of gastrointestinal dysbiota towards healthy and multivariate microbiota to restore physiologic status. One of the main focuses has been dietary fiber (DF), in which most of its variants are prebiotics. The highest effective treatment for NAFLD is, so far, weight loss achieved by caloric restriction. DF supplementation with oligofructose facilitates weight loss, enhances the production of beneficial metabolites, decreases some pathogenic bacteria population by increasing Bifidobacteria , and has effects on intestinal barrier permeability. DF use has been associated with improvement in diverse metabolic diseases, including NAFLD, by modifying gut microbiota. Additionally, it has been shown that a higher insoluble fiber consumption (≥7.5 g/day) revealed improvements in 3 different scores of liver fibrosis. Further research is needed, but given the evidence available, it is reasonable to prescribe its consumption in early stages of NAFLD in order to prevent disease progression. |
